9 Amendments of Sandra PEREIRA related to 2020/2071(INI)
Amendment 6 #
Draft opinion
Recital A
Recital A
A. whereas the coronavirus pandemic has exacerbated the growing problem of medicine shortages across the EU; whereas the ensuing disruption of the global supply chain has highlighted the EU’s dependency on third countdeficiencies of market mechanisms with research and development, production and trade controlled by multinational enterprises, and the EU’s dependency on these for medicines and active pharmaceutical ingredients;
Amendment 17 #
Draft opinion
Recital A a (new)
Recital A a (new)
A a. Recognizes that drug shortages are sometimes artificially created by pharmaceutical companies that choose to produce more profitable drugs while neglecting less profitable ones;
Amendment 50 #
Draft opinion
Paragraph 1
Paragraph 1
1. Insists that the Commission urgently launches a multi-stakeholder consultation to identify key supply chain issues that directly cause or increase the risk of medicine shortages; calls on the Commission to propose ambitious and concrete actions to address these issues in its planned pharmaceutical strategy with, among others, a mechanism to oblige the companies owning the patents to produce the needed medicines even if they are less profitable, and the possibility to impose compulsory licences in order to facilitate, without constraint, the increase of the production of the most needed drugs or vaccines;
Amendment 85 #
Draft opinion
Paragraph 3
Paragraph 3
3. Stresses the urgent need for the EU to reduce its over-reliance on a small number of third countries for medicine manufacturing and as sources of active pharmaceutical ingredients; calls therefore the EU to enable the creation of a European public pharmaceutical hub which will have the responsibility to ensure the production of essential drugs and vaccines and make them available at cost price to the health departments of Member States;
Amendment 88 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3 a. Stresses the urgent need to ensure that patents are not a barrier to securing supplies during any epidemic outbreak; stresses the need to override patents for drugs, vaccines, and medical equipment as needed to secure critical supplies during any epidemic outbreak, present and future, by licensing public laboratories and industries to make generic copies of brand-name products without having to negotiate with patent holders;
Amendment 95 #
Draft opinion
Paragraph 3 b (new)
Paragraph 3 b (new)
3 b. Stresses that the urgent need for medicines and medical equipment cannot mean, nor be at the expense of the quality, safety, efficacy and cost-effectiveness of medicines for human use and health products, including medical devices and products cosmetics and body hygiene;
Amendment 96 #
Draft opinion
Paragraph 3 c (new)
Paragraph 3 c (new)
3 c. Recalls that compliance with the rules applicable to the authorization of clinical trials with medicines, as well as the control of observance of good clinical practices in their performance, must continue to be regulated and supervised according to the highest standards of public health protection, to guarantee the access of health professionals and citizens to quality, effective and safe medicines and health products;
Amendment 99 #
Draft opinion
Paragraph 3 d (new)
Paragraph 3 d (new)
3 d. Recalls the words of the United Nations Secretary-General who recently declared that the future treatment for Covid-19 is "a public good" that should be made available to all; warns that the defense of public health does not match the presumption of profit, which will always be obtained at the expense of the suffering of the peoples;
Amendment 124 #
Draft opinion
Paragraph 5
Paragraph 5
5. Highlights the fact that Horizon 2020 has already financed a significant number of health-related research and innovation activities; calls for more funding to be provided through Horizon Europe to create and support medicine- focused research ecosystems.public-owned research;